Login to Your Account

HGS Signs Albuferon Deal With Novartis Worth Up To $550M

By Aaron Lorenzo

Wednesday, June 7, 2006
Human Genome Sciences Inc. could earn more than half a billion dollars per terms of a newly formed agreement with Novartis AG on Albuferon (albumin-interferon alpha 2b), a product expected to move into Phase III for chronic hepatitis C by the end of this year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription